Format

Send to

Choose Destination
Ther Innov Regul Sci. 2016 Mar;50(2):155-168. Epub 2015 Oct 8.

Birth Control in Clinical Trials: Industry Survey of Current Use Practices, Governance, and Monitoring.

Author information

1
AstraZeneca, Macclesfield, United Kingdom.
2
Lilly Research Laboratories, Indianapolis, IN, USA.
3
Sanofi U.S. Inc, Bridgewater, NJ, USA.
4
Bristol-Myers Squibb, New Brunswick, NJ, USA.
5
Janssen R&D, Beerse, Belgium.
6
AbbVie Inc, North Chicago, IL, USA.
7
McMaster University, Hamilton, Ontario, Canada.
8
Celgene Corp, Summit, NJ, USA.
9
Amgen Inc, Thousand Oaks, CA, USA.
10
Federal Agency for Medicines and Health Products, Brussels, Belgium.
11
Federal Institute for Drugs and Medical Devices, Bonn, Germany.
12
ILSI-Health and Environmental Sciences Institute, Washington, DC, USA.

Abstract

The Health and Environmental Sciences Institute (HESI) Developmental and Reproductive Toxicology Technical Committee sponsored a pharmaceutical industry survey on current industry practices for contraception use during clinical trials. The objectives of the survey were to improve our understanding of the current industry practices for contraception requirements in clinical trials, the governance processes set up to promote consistency and/or compliance with contraception requirements, and the effectiveness of current contraception practices in preventing pregnancies during clinical trials. Opportunities for improvements in current practices were also considered. The survey results from 12 pharmaceutical companies identified significant variability among companies with regard to contraception practices and governance during clinical trials. This variability was due primarily to differences in definitions, areas of scientific uncertainty or misunderstanding, and differences in company approaches to enrollment in clinical trials. The survey also revealed that few companies collected data in a manner that would allow a retrospective understanding of the reasons for failure of birth control during clinical trials. In this article, suggestions are made for topics where regulatory guidance or scientific publications could facilitate best practice. These include provisions for a pragmatic definition of women of childbearing potential, guidance on how animal data can influence the requirements for male and female birth control, evidence-based guidance on birth control and pregnancy testing regimes suitable for low- and high-risk situations, plus practical methods to ascertain the risk of drug-drug interactions with hormonal contraceptives.

KEYWORDS:

clinical trials; contraception; industry approaches; informed consent

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center